<DOC>
	<DOCNO>NCT00828932</DOCNO>
	<brief_summary>The purpose study evaluate establish whether lorcaserin dose adjustment require patient mild moderate hepatic impairment .</brief_summary>
	<brief_title>Pharmacokinetic Properties Lorcaserin Subjects With Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>1 . Males female age 18 75 year ( inclusive ) 2 . Able give sign informed consent 3 . Hepatic function fall one follow category : Onethird patient normal hepatic function ( define follow parameter within normal range clinical laboratory use trial : AST , ALT , alkaline phosphatase , total bilirubin ) Onethird patient mild impairment ( ChildPugh score 56 ) Onethird patient moderate impairment ( ChildPugh score 79 ) 4 . All subject BMI 2745 kg/m2 , inclusive . 5 . Eligible male female patient must agree participate conception process 6 . Considered stable health opinion Investigator . 1 . Prior participation study lorcaserin . 2 . Clinically significant new illness 1 month screen 3 . Not suitable participate study opinion Investigator include exist physical mental condition prevents compliance protocol 4 . History follow cardiovascular condition : Myocardial infarction ( diagnosed cardiac enzyme [ ] and/or diagnostic ECG ) , CVA , TIA RIND within 6 month screen Cardiac arrhythmia require initiation new medical surgical treatment within 6 month screen ( stable medical therapy &gt; 6 month , pacemaker and/or defibrillator implant &gt; 6 month prior screen acceptable ) Unstable angina 5 . Surgically implanted portacaval shunt exclude follow exception : transjugular intrahepatic portosystemic shunt ( TIPS ) allow place less 3 month prior dose 6 . Malignancy within 2 year screen visit ( except basal cell squamous cell carcinoma clean surgical margin ) 7 . Initiation new prescription medication within 1 month prior screen . 8 . Recent history ( within 3 month prior screen visit ) alcohol drug/solvent abuse positive screen drug abuse screen . 9 . Use SSRI 's , SNRI 's , medication must meet require washout period . 10 . Participated clinical study investigational drug , biologic , device within 1 month prior dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>